Third Rock­'s Am­bys hauls $140M for liv­er dis­ease, ink­ing Take­da deal ahead of launch

It won’t shock any­one that a new com­pa­ny has rolled off Third Rock’s start­up con­vey­or belt (this VC firm is a ma­chine at cre­at­ing new com­pa­nies), but their lat­est ven­ture is leap­ing off the start line with a dis­tinct ad­van­tage: $140 mil­lion in launch mon­ey and a rare deal with Big Phar­ma part­ner Take­da.

The new com­pa­ny is called Am­bys Med­i­cines, chris­tened af­ter the Mex­i­can sala­man­der famed for re­gen­er­at­ing limbs: Am­bystoma mex­i­canum. You guessed it, the com­pa­ny will be work­ing in re­gen­er­a­tive med­i­cine.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER